Group 1 - The company, Shanghai Jianda Zhixin Medical Technology Group Co., Ltd., has issued a voluntary performance forecast for the fiscal year 2025, indicating that the net profit attributable to shareholders is expected to be positive and show an upward trend [1][3] - The performance forecast period is from January 1, 2025, to December 31, 2025 [1] - The company has communicated with its auditing firm regarding the performance forecast, and there are no discrepancies between the company and the auditors [2] Group 2 - The company's medical consumables centralized operation (SPD) business is experiencing rapid growth, contributing to an increase in overall profitability due to its high gross profit margin [3] - The company has optimized its financial structure, resulting in a year-on-year decrease in interest-bearing debt and a reduction in financing costs through negotiations with financial institutions, positively impacting net profit [3]

Group 1 - The company has issued a voluntary performance forecast for the period from January 1, 2025, to December 31, 2025, expecting a positive net profit attributable to shareholders and a positive net profit after deducting non-recurring gains and losses, both showing an upward trend [1] - The preliminary data for the performance forecast has been calculated by the company's finance department and has not yet been audited by an external auditor. There are no discrepancies between the company and the auditing firm regarding this performance forecast [1] - The increase in performance is attributed to the rapid development of the company's centralized operation of medical consumables (SPD) business, which has a high gross profit margin, enhancing the overall profitability of the company. Additionally, the company has optimized its financial structure, reducing interest-bearing debt year-on-year and lowering financing costs through negotiations with financial institutions, positively impacting net profit [1]

Core Viewpoint - The company Jianfa Zhixin (301584.SZ) expects a net profit attributable to shareholders of 242 million to 296 million yuan for 2025, representing a year-on-year growth of 6.00% to 29.65% [1] Financial Performance - The net profit after deducting non-recurring gains and losses is projected to be between 232 million and 286 million yuan, indicating a year-on-year increase of 3.77% to 27.93% [1] - The company has optimized its financial structure, resulting in a year-on-year decrease in interest-bearing debt [1] - Through communication and negotiation with financial institutions, the company has successfully reduced financing costs, leading to a decrease in financial expenses and positively impacting net profit [1] Business Development - The company's medical consumables centralized operation (SPD) business has maintained rapid growth, contributing to a higher gross profit margin and enhancing overall profitability [1]

Core Viewpoint - The company Jianfa Zhixin expects a net profit attributable to shareholders of 242 million to 296 million yuan for 2025, representing a year-on-year growth of 6% to 29.65% due to the rapid development of its medical consumables centralized operation (SPD) business, which has a high gross profit margin [1] Group 1 - The company's SPD business is experiencing rapid growth, contributing significantly to overall profitability [1] - The gross profit margin of the SPD business is high, enhancing the company's overall profitability [1] - The company is optimizing its financial structure, resulting in a year-on-year decrease in interest-bearing liabilities [1] Group 2 - The company has engaged in communication and negotiation with financial institutions to reduce financing costs, positively impacting net profit [1] - Financial expenses have decreased year-on-year, further contributing to the increase in net profit [1]